49LOW

MAP

MICROBA FPO [MAP]
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Healthcare · ASX Small Cap
$0.0780 +11.4%

Updated 26 Mar 2026 · Scores refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.

Score Breakdown

Technical51
Catalyst50
Sentiment50
Fundamental65
Momentum41
Risk Gate50
Get alerts when MAP's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track MAP — Free

Active Signals

Bullish Signals

  • Low cash runway (3 quarters) - dilution risk
  • 4C filed 2026-01-28
  • Low P/S ratio (2.9x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (1% of range)
  • Small-cap ($20-100M)
  • CANSLIM S: Tight float (41%)
  • CANSLIM I: Institutional ownership (21%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.47%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-10%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-133%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 45% over the past year
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about MAP
"What's driving MAP's score?" "How does MAP compare to peers?" "Key risks for MAP?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4D & FY26 Interim Report
LOW Q2 FY26 Quarterly Investor Presentation & Webinar
LOW Q2 FY26 Quarterly Activities Report & Appendix 4C

Recent ASX Announcements

2026-02-25 Appendix 4D & FY26 Interim Report PRICE SENSITIVE
2026-01-28 Q2 FY26 Quarterly Investor Presentation & Webinar PRICE SENSITIVE
2026-01-28 Q2 FY26 Quarterly Activities Report & Appendix 4C PRICE SENSITIVE

Key Metrics

$42.6M
Market Cap
109K
Avg Volume
1.0x
Vol Ratio
$0.07 — $0.23
52-Week Range
N/A
Short Interest
3 qtrs
Cash Runway
-60.0%
ROE
-132.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 41%
LLeader vs LaggardlaggardRS: 1
IInstitutional SponsorshippassInst: 21%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #46 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:MAP vs ATXMAP vs PNVMAP vs IMM
Scout Pro — Deeper Analysis for MAP
Try Pro free for 30 days
Share this analysis

Track MAP and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required